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OBJECTIVES: The aim of this study was to measure cancer-related direct expen-
ditures and its determinants, from the third-party payer perspective, for patients 
newly diagnosed and treated by the National Health System (SUS) from 2000 
to 2003. METHODS: We used data from national administrative registries of all 
patients treated by the SUS. We restricted our sample to patients newly diagnosed 
between the years 2000 and 2003 with the most prevalent cancers in Brazil (breast, 
cervix, prostate, lung, colorectal and stomach). Data included expenditures related 
to chemotherapy and radiotherapy and in-patient care. A generalized linear model 
with a gamma distribution was used to estimate the determinants of healthcare 
expenditures. Regressions were performed for the whole sample and then sepa-
rately by cancer type. RESULTS: A total 180,283 patients were diagnosed with cancer 
between 2000 and 2003: 38.6% breast, 19.1% cervix, 15.4% prostate, 11.3% lung, 10.8% 
colorectal and 4.9% stomach cancer. Average monthly expenditures were 315$ and 
the average follow-up of 18 months. The highest average monthly expenditure was 
observed for lung cancer (649$) followed by stomach cancer (382$). High discrep-
ancies were observed between states, from 210$ (Maranhão) to 471$ (Roraima). 
All covariates were significantly related to expenditures. Monthly expenditures 
decreased with follow-up time and increased with death and presence of metas-
tases. Expenditures were lower among women and decreased continuously with 
patient’s age, with the lowest expenditures observed among patients older than 80. 
As compared to cancer in situ, lower expenditures were observed for stage I; by con-
trast, expenditures were much higher at stage III and IV. Covariates behaved simi-
larly across cancer types, except for the stage of disease. CONCLUSIONS: Average 
monthly expenditures for cancer treatment in Brazil are relatively low as compared 
e.g. to estimates for the US. The strong discrepancy between States raises serious 
concerns about equity and quality.
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OBJECTIVES: NPS MedicineWise Australia developed and implemented a multi-
faceted academic detailing program to improve general medical practitioner pre-
scribing of antipsychotic therapy. A significant component of this program focused 
on the appropriate use of medicines for older people with dementia. Evidence has 
demonstrated that older adults in community and residential aged care facilities 
are prescribed antipsychotics for the management of their dementia symptoms 
despite lack of evidence of benefit. This study is an economic evaluation of the NPS 
MedicineWise educational program in terms of reduced falls and stroke incidence 
due to reduction in antipsychotic prescribing including olanzapine, quetiapine 
and risperidone METHODS: A cost-benefit analysis was performed to evalu-
ate the costs and benefits of preventing hospitalisations due to strokes and falls 
as a result of reduced antipsychotic prescribing due to the program. A decision 
tree model was constructed using TreeAge Pro 2014. Data sources were from our 
clinical audit, general practitioner survey and interrupted time series analyses of 
administrative data from the Australian Pharmaceutical Benefits Scheme (PBS). A 
meta-analysis was conducted to provide outcome data on the reduction of antipsy-
chotics. Probabilistic sensitivity analysis was performed to address any parameter 
uncertainty using Monte Carlo simulation. RESULTS: Following implementation of 
the NPS MedicineWise intervention, a reduction in prescription of atypical antip-
sychotics among older adults was observed in the PBS. Modelling of this reduction 
translated into a reduction in the incidence of both stroke and fall hospitalisations 
among this cohort resulting in costs avoided for Government. CONCLUSIONS: This 
is a comprehensive economic analysis conducted in Australia to have utilised PBS 
data and large scale evaluation results to examine interventions focussing on the 
appropriate use of medicines in older adults. The results will be used to further 
inform future public health interventions aimed at managing the health outcomes 
of this vulnerable and growing population.
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OBJECTIVES: Our clinical trial compared two behavioral psychosocial interventions 
tailored for children with ADHD-inattentive type (ADHD-I) which varied in intensity 
and outcomes. We evaluated cost-effectiveness of the Child Life and Attention Skills 
(CLAS) program, which has parent, teacher and child sessions, and the parent-
focused treatment (PFT), which includes only parent sessions, both compared with 
traditional community treatment (TAU). METHODS: We used our recent clinical trial 
for data on resources used and treatment outcomes. Our CEA outcome was cost 
per ADHD case avoided as measured by the Child Symptom Inventory. Costs for 
CLAS and PFT included clinician, parent, and teacher time, supplies, and childcare. 
TAU costs included only supplies. Salaries were from Bureau of Labor Statistics in 
2011 USD. Savings were calculated from reductions in parent time spent on home-
work and lost leisure and work time based on surveys taken before and 7 months 
post-treatment. Sensitivity analyses assessed the impact of altering CLAS struc-
ture, including having personnel of varying educational background lead group 
sessions. RESULTS: Total cost per patient for CLAS, PFT, and TAU were $1,655.04, 
$795.03, and -$9.37, respectively. CLAS, the costliest, was also more effective than 
PFT and TAU; 39, 34, and 11 cases avoided. The incremental cost-effectiveness ratio 
(ICER) was $4,368.63 per disordered case avoided for CLAS compared to TAU. PFT 
compared to TAU was lower at $2,564.56. The ICER of CLAS compared to PFT was 
$12,684.49. Reducing the number and length of group meetings resulted in an ICER of 
$3,333.05 for CLAS compared to TAU. CONCLUSIONS: PFT is the more cost-effective 
treatment option for children with ADHD-I given delivery based on our clinical trial. 
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OBJECTIVES: Unreported adverse drug reactions (ADRs) are of big concerns to 
medication safety in the outpatient setting. To improve ADR reporting, we used a 
Telephonic Interactive Voice Response System (IVRS) that interoperates with EHR 
(electronic health records) and pharmacist to assess and detect possibility of ADRs 
symptoms related to outpatient medications. In this study we estimated the cost 
of possible ADR symptoms reporting using IVRS. METHODS: 5872 eligible patients 
from a large health system in greater Boston were identified. To be eligible they had 
to be an adult patient seen in primary care at one of 8 participating clinics, received 
a new prescription for an oral medication to treat hypertension, diabetes, depres-
sion, or insomnia. Using IVRS, we contacted patients 4-6 weeks and again at 4-6 
months after the date the drug was prescribed, to document any patient-reported 
symptoms related to ADRs. Costs per patient contacted, respondent patient, and 
patient reporting a possible ADR were estimated. Direct health care costs and cost 
of patient’s time for the intervention were included in the analysis. Costs of health 
care resources and personnel were derived from the hospital financial accounting 
system. RESULTS: Of the total patients contacted (5872), 10.3% responded, 7.3% 
were transferred to pharmacist and 5.2% reported symptoms to the IVRS. The total 
cost per patient contacted was estimated at $12.29. Pharmacist’s salary represented 
66.7% of the cost per patient contacted. The cost per respondent patient, cost per 
call transferred to pharmacist and cost of symptoms reported per patient were 
estimated to be $118.51, $167.85 and $235.86 respectively. CONCLUSIONS: Systems 
like IVRS with real-time linkages to a clinical pharmacist, may facilitate early detec-
tion of possible ADRs related to prescription medications and do so with relatively 
little cost per patient. Earlier detection of adverse drug reactions may help reduce 
the costs related to primary care visits and hospitalizations.
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